Cantor Fitzgerald set a $45.00 price target on Dermira (NASDAQ:DERM) in a research report report published on Monday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
“We received a lot of questions regarding DERM’s stock strength on Friday, Jan. 12 (stock closed up 2.77% and was up ~9% intraday versus S&P 500, which closed up 0.67%).”,” the firm’s analyst wrote.
Several other research analysts have also weighed in on the company. Zacks Investment Research raised Dermira from a sell rating to a hold rating in a research report on Tuesday, January 9th. BidaskClub lowered Dermira from a buy rating to a hold rating in a research report on Tuesday, January 9th. Guggenheim reaffirmed a buy rating and issued a $30.00 target price on shares of Dermira in a research report on Thursday, December 14th. Mizuho dropped their target price on Dermira from $43.00 to $39.00 and set a buy rating on the stock in a research report on Tuesday, December 12th. Finally, Leerink Swann reaffirmed an outperform rating and issued a $41.00 target price (down from $47.00) on shares of Dermira in a research report on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $41.00.
Shares of Dermira (NASDAQ:DERM) traded up $0.74 during mid-day trading on Monday, reaching $27.44. The company’s stock had a trading volume of 1,063,400 shares, compared to its average volume of 800,144. The company has a debt-to-equity ratio of 1.40, a quick ratio of 4.68 and a current ratio of 4.68. Dermira has a 12 month low of $21.35 and a 12 month high of $38.75. The firm has a market cap of $1,143.54, a price-to-earnings ratio of -4.40 and a beta of 0.80.
Dermira (NASDAQ:DERM) last issued its earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.09). Dermira had a negative return on equity of 41.22% and a negative net margin of 992.18%. sell-side analysts forecast that Dermira will post -7.36 earnings per share for the current fiscal year.
In other news, CEO Thomas G. Wiggans sold 5,000 shares of the stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $27.51, for a total transaction of $137,550.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Eugene A. Bauer sold 3,000 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $27.07, for a total value of $81,210.00. Following the transaction, the insider now directly owns 5,802 shares in the company, valued at approximately $157,060.14. The disclosure for this sale can be found here. In the last three months, insiders have sold 36,258 shares of company stock worth $985,873. 13.30% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA increased its holdings in shares of Dermira by 2,220.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 3,975 shares during the last quarter. Quantbot Technologies LP increased its holdings in shares of Dermira by 75.4% during the 3rd quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock valued at $145,000 after acquiring an additional 2,309 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Dermira by 66.8% during the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 2,203 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Dermira by 40.9% during the 2nd quarter. Legal & General Group Plc now owns 9,664 shares of the biopharmaceutical company’s stock valued at $281,000 after acquiring an additional 2,803 shares during the last quarter. Finally, Ardsley Advisory Partners bought a new stake in Dermira during the 2nd quarter valued at approximately $291,000. 99.47% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This article was first reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.truebluetribune.com/2018/01/16/dermira-derm-given-a-45-00-price-target-at-cantor-fitzgerald.html.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.